MARKET

UTHR

UTHR

Utd Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

116.92
-0.86
-0.73%
Closed 16:00 07/09 EDT
OPEN
117.62
PREV CLOSE
117.78
HIGH
118.52
LOW
115.92
VOLUME
201
TURNOVER
--
52 WEEK HIGH
127.79
52 WEEK LOW
74.31
MARKET CAP
5.15B
P/E (TTM)
9.75
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average UTHR stock price target is 141.11 with a high estimate of 243.00 and a low estimate of 90.00.

EPS

UTHR News

More
XBI: Not Everybody Can Be A Hero
Seeking Alpha - Article · 2d ago
3 Perfect 10 Healthcare Stocks That Have Plenty of Growth on Tap
TipRanks · 2d ago
The Perfect 10 Portfolio Rides Again
GuruFocus.com · 3d ago
3 Health Care Companies That Beat the Market in the 1st Half of the Year
GuruFocus screener identifies top performers amid coronavirus pandemic Continue reading...
GuruFocus.com · 06/30 21:18
United Therapeutics extends Lilly Adcirca deal three years
Seeking Alpha - Article · 06/29 10:38
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25)
Benzinga · 06/26 12:28
Regeneron Used a Charity to Pay Kickbacks, Justice Department Alleges
marketwatch.com · 06/26 09:41
Credit Suisse tells clients to bet on a small cap breakout and gives stocks to buy
"Small caps are more cyclical and less diversified businesses and thus do well as the economic cycle recovers," a strategist said.
CNBC.com · 06/25 17:49

Industry

Biotechnology & Medical Research
-0.44%
Pharmaceuticals & Medical Research
-0.78%

Hot Stocks

Symbol
Price
%Change

About UTHR

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.
More

Webull offers kinds of United Therapeutics Corporation stock information, including NASDAQ:UTHR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UTHR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading UTHR stock methods without spending real money on the virtual paper trading platform.